Render Target: SSR
Render Timestamp: 2025-03-20T20:23:06.897Z
Commit: 779953b12a5930618aae6aca7c87fb286faeb1d7
XML generation date: 2025-03-07 13:13:05.662
Product last modified at: 2025-01-01T09:04:42.423Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

Receptor Tyrosine Kinase Antibody Sampler Kit #42344

    Product Information

    Product Description

    The Receptor Tyrosine Kinase Antibody Sampler Kit provides the means to detect a broad range of common receptor tyrosine kinases, as well as total phospho-tyrosine activity. The kit provides enough antibody to perform two western blot experiments with each primary antibody.

    Background

    Tyrosine phosphorylation plays a key role in cellular signaling (1). In cancer studies, unregulated tyrosine kinase activity can drive malignancy and tumor formation by generating inappropriate proliferation and survival signals (2). Antibodies specific for phospho-tyrosine have been invaluable reagents in these studies (3,4).

    Met, a tyrosine kinase receptor for hepatocyte growth factor (HGF), is a heterodimer made of α- and β-subunits (5,6). The cytoplasmic region of the β-chain is essential for tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines (Tyr1003, 1234/1235, 1349) which recruit downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (7-9). Altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast (10,11).

    The epidermal growth factor (EGF) receptor is a transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling, internalization, and lysosomal degradation (12,13). c-Src mediated phosphorylation of EGF receptor (EGFR) at Tyr845 provides a binding surface for substrate proteins (14-16). The SH2 domain of PLCγ binds at phospho-Tyr992, activating PLCγ-mediated downstream signaling (17). Adaptor protein c-Cbl binds at phospho-Tyr1045, leading to receptor ubiquitination and degradation (18,19). The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068 (20), while phospho-Tyr1148 and -Tyr1173 provide a docking site for the Shc scaffold protein, playing a role in MAP kinase signaling (13).

    Platelet derived growth factor (PDGF) family proteins bind to two closely related receptor tyrosine kinases, PDGF receptor α (PDGFRα) and PDGF receptor β (PDGFRβ) (21). PDGFRα and PDGFRβ can each form heterodimers with EGFR, which is also activated by PDGF (22). Ligand binding induces receptor dimerization and autophosphorylation, followed by binding and activation of signal transduction molecules such as GRB2, Src, GAP, PI3 kinase, PLCγ, and NCK. Signaling pathways initiated by activated PDGF receptors lead to control of cell growth, actin reorganization, migration, and differentiation (23). Tyr751 and Tyr740 of PDGFRβ regulate binding and activation of PI3 kinase (24,25).

    Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases, after ligand binding and dimerization (26,27). Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling (28). The other phosphorylated tyrosine residues (Tyr463, 583, 585, 730, and 766) may provide docking sites for downstream signaling components such as Crk and PLCγ (29,30).

    FMS-related tyrosine kinase 3 (FLT3), a member of the type III receptor tyrosine kinase family, is expressed on early hematopoietic progenitor cells and supports growth and differentiation within the hematopoietic system (31,32). FLT3 is activated after binding with its ligand FL, which results in a cascade of tyrosine autophosphorylation and tyrosine phosphorylation of downstream targets (33). The p85 subunit of PI3 kinase, SHP2, GRB2 and Shc are associated with FLT3 after FL stimulation (34-36). Tyr589/591 may play an important role in regulation of FLT3 tyrosine kinase activity (37).

    The ErbB2 (HER2) proto-oncogene encodes a transmembrane, receptor-like glycoprotein with tyrosine kinase activity (38). ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through associations with other ErbB family members (39). Phosphorylation at Tyr877 may be involved in regulating ErbB2 activity. Autophosphorylation of ErbB2 at Tyr1248 and Tyr1221/1222 couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (38,40).
    1. Schlessinger, J. (2000) Cell 103, 211-25
    2. Blume-Jensen, P. and Hunter, T. (2001) Nature 411, 355-65
    3. Ward, S.G. et al. (1992) J Biol Chem 267, 23862-9
    4. Glenney, J.R. et al. (1988) J Immunol Methods 109, 277-85
    5. Cooper, C.S. et al. Nature 311, 29-33.
    6. Bottaro, D.P. et al. (1991) Science 251, 802-4.
    7. Bardelli, A. et al. (1997) Oncogene 15, 3103-11.
    8. Taher, T.E. et al. (2002) J Immunol 169, 3793-800.
    9. Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.
    10. Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.
    11. Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.
    12. Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9.
    13. Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12.
    14. Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-4.
    15. Hubbard, S.R. et al. Nature 372, 746-54.
    16. Biscardi, J.S. et al. (1999) J Biol Chem 274, 8335-43.
    17. Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86.
    18. Levkowitz, G. et al. (1999) Mol Cell 4, 1029-40.
    19. Ettenberg, S.A. et al. (1999) Oncogene 18, 1855-66.
    20. Rojas, M. et al. (1996) J Biol Chem 271, 27456-61.
    21. Deuel, T.F. et al. (1988) Biofactors 1, 213-7.
    22. Betsholtz, C. et al. (2001) Bioessays 23, 494-507.
    23. Ostman, A. and Heldin, C.H. (2001) Adv Cancer Res 80, 1-38.
    24. Panayotou, G. et al. (1992) EMBO J 11, 4261-72.
    25. Kashishian, A. et al. (1992) EMBO J 11, 1373-82.
    26. Powers, C.J. et al. (2000) Endocr Relat Cancer 7, 165-97.
    27. Reilly, J.F. et al. (2000) J Biol Chem 275, 7771-8.
    28. Mohammadi, M. et al. (1996) Mol Cell Biol 16, 977-89.
    29. Mohammadi, M. et al. (1991) Mol Cell Biol 11, 5068-78.
    30. Larsson, H. et al. (1999) J Biol Chem 274, 25726-34.
    31. Shurin, M.R. et al. (1998) Cytokine Growth Factor Rev 9, 37-48.
    32. Naoe, T. et al. (2001) Cancer Chemother Pharmacol 48 Suppl 1, S27-30.
    33. Namikawa, R. et al. (1996) Stem Cells 14, 388-95.
    34. Beslu, N. et al. (1996) J Biol Chem 271, 20075-81.
    35. Zhang, S. and Broxmeyer, H.E. (2000) Biochem Biophys Res Commun 277, 195-9.
    36. Zhang, S. et al. (1999) J Leukoc Biol 65, 372-80.
    37. Mizuki, M. et al. (2000) Blood 96, 3907-14.
    38. Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.
    39. Qian, X. et al. (1994) Proc Natl Acad Sci U S A 91, 1500-4.
    40. Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    MultiMab is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.